VEEVA SYSTEMS INC

VEEVA’s insider sale and Medisights’ AI‑driven oncology study highlight the company’s transparency, AI push and growth potential for data‑governed market insight.

Veeva Systems’ Q2 2026 earnings show a 12% revenue jump, AI‑driven Vault and Falcon growth, and strong margins—highlighting its cloud‑based life‑sciences advantage.

VEEVA SYSTEMS INC. tops the options‑volatility brief with the largest projected earnings move, hinting at a market‑shifting announcement for tech and software investors.

Veeva Systems’ Q1 2026 earnings will gauge cloud‑based life‑science tech’s growth, regulatory impact, and market sentiment amid a tech earnings storm.

Veeva Systems’ sharp stock surge sparks analyst buzz, offering traders a fresh price‑momentum signal amid growing SaaS growth and market‑value re‑assessment.

Veeva Systems’ 8‑K filing announces Dan Rizzo as EVP of Sales, Consulting & Services as Thomas Schwenger departs, signaling a strategic shift in leadership and market focus.

Veeva Systems jumps 8% amid a resilient healthcare rally, beating the S&P downturn and attracting investors with its undervalued cloud‑based life‑science solutions.

Veeva Systems expands its cloud suite—Quality Cloud, Vault CRM, and Falcon—boosting AI‑enabled efficiency, compliance, and drug‑development speed for pharma leaders.

Veeva Systems to release fiscal 2027 Q1 earnings on June 3; learn how its AI‑powered cloud platform drives 26% revenue growth, 73% gross margin, and faster drug market access.

Veeva’s May 2026 filings reveal board confidence, a $2 billion share‑buyback, and new governance moves as the company hits the S&P 500, boosting investor trust and positioning in life‑science cloud tech.